Perhaps as an adjunct or even as a replacement, EPCA-2 represents one of many potential new biomarkers, which may help patients better determine their risk for having prostate cancer and even avoid unnecessary biopsies.
"Practicing urologists are all too familiar with two common problems inherent in the management of prostate cancer: the lack of specificity of the PSA test and the lack of a method to distinguish between progressive and indolent disease. A new biomarker, which is under investigation at Johns Hopkins, shows great potential to address both of these controversial issues..." For more, click here
